The Biosimilar Monoclonal Antibodies Market is driven by rituximab and infliximab submarkets, the rituximab submarket is accounted as the highest holding market share submarket and the infliximab submarket will become the leading submarket by 2018 continuing its dominance until 2022. A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. A monoclonal antibody is made so that it binds to only one substance to treat different types of cancer. There are several types of monoclonal antibodies that are being used to treat certain types of cancer. Laboratory production of monoclonal antibodies is produced from clones of only one cell which means that every monoclonal antibody produced by the cell is the same due to which they are called as biosimilar monoclonal antibodies. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting, hence different monoclonal antibodies are required to be made to target different types of cancers.

In 2014, the size of the global biosimilar monoclonal antibodies market was valued over USD 352 million. While in 2015, the market size reached to USD xxx.x million. The global biosimilar monoclonal antibodies market is projected to grow with a CAGR between 42.9% and 43.5% during 2016-2022 and reach USD xxxx.x million by 2022. Patient expiration of biologics, innovative product in the pipeline and increasing healthcare infrastructure are expected to be key factors driving the growth of global biosimilar monoclonal antibodies market. However, unfavorable government regulations and development policies, undesirable manufacturing process and cost structure associated with the manufacturing process are considered to be restraining factors in the global biosimilar monoclonal antibodies market. Furthermore, increasing demand for cost effective treatment, collaboration with the local players and high profitability in the market are the key opportunities for the companies to invest in the biosimilar monoclonal antibodies market.

Segments Covered:

The report segments the global biosimilar monoclonal antibodies market by drug class and by application.The market segmentation based on drug class includes, rituximab, infliximab, abciximab, trastuzumab, adalimumab, and bevacizumab. Moreover, based on application the biosimilar monoclonal antibodies market is segmented into oncology, chronic and auto immune diseases, growth hormone deficiency and infectious diseases.

Geographic Coverage and Analysis:

The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, Latin America, and Rest of the World (RoW). Europe is the largest biosimilar monoclonal antibodies market globally. Due to favorable regulatory policies designed by the European Medical Association (EMA) and since Europe was the first region to draft guidelines for approval of biosimilar products, the European market has a largest these market share on the market. Asia pacific is expected to grow at the highest CAGR over the forecast period and provides the opportunity to market growth due to increasing demand of cost effective treatment to the prevalence of chronic diseases and launch of new biosimilar monoclonal antibodies. Nevertheless, government investment in healthcare will also act as a growth opportunity for biosimilar monoclonal antibodies market in the Asia-Pacific region.

Companies Profiled:

The companies covered in the report include

Pfizer Inc
Novartis AG
Reliance Life Sciences
Allergan plc
Coherus BioSciences Inc
Biocon
Dr. Reddy’s Laboratories Ltd.
Boehringer Ingelheim GmbH
BioXpress Therapeutics SA
Intas Pharmaceuticals Limited
BIOCAD
Genor BioPharma Co. Ltd
Celltrion Inc